http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 13 Oct 2026 08:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Dianthus+Therapeutics+Recognized+Among+Fortune%E2%80%99s+2026+Best+Workplaces+In+BioPharma/27178001.html <p>NEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced it was selected by Great Place To Work® and <em>Fortune </em>magazine for the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=K4afluDVP3c-li-9DLIVCyecm3xYQgPehPQzeMUUG4fJateTCigKQAszCDtDy6m6QVqc4VFw0gKRkgbiAQ6ojWfU_-wwGxRG2c6QrdNUM7K-YE0IjT4QZE74VuGDbvmSExI0OQA-zz71WhZe0JbDhVIyM17VCZmYF1K2eSkTi3ffzuWmzWr1OloEnDsM4rNG1H8roUg0cGt6zFD_Uf7FheuNE1SWN9bIC9ameMXPO4A=" rel="nofollow" target="_blank">2026 <em>Fortune</em> Best Workplaces in BioPharma™ List</a>. This is Dianthus’ inaugural appearance on the list, ranking among the top 30 small- and medium-sized biotechnology and pharmaceutical companies in the United States. The Company was recognized for fostering a high-trust and engaging workplace culture.</p> <p>“As Dianthus http://www.streetinsider.com/Press+Releases/Dianthus+Therapeutics+Recognized+Among+Fortune%E2%80%99s+2026+Best+Workplaces+In+BioPharma/27178001.html Tue, 13 Oct 2026 08:45:00 -0400 DNTH http://www.streetinsider.com/Globe+Newswire/Dianthus+Therapeutics+Recognized+Among+Fortune%E2%80%99s+2026+Best+Workplaces+In+BioPharma/27178001.html <p>NEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced it was selected by Great Place To Work® and <em>Fortune </em>magazine for the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=K4afluDVP3c-li-9DLIVCyecm3xYQgPehPQzeMUUG4fJateTCigKQAszCDtDy6m6QVqc4VFw0gKRkgbiAQ6ojWfU_-wwGxRG2c6QrdNUM7K-YE0IjT4QZE74VuGDbvmSExI0OQA-zz71WhZe0JbDhVIyM17VCZmYF1K2eSkTi3ffzuWmzWr1OloEnDsM4rNG1H8roUg0cGt6zFD_Uf7FheuNE1SWN9bIC9ameMXPO4A=" rel="nofollow" target="_blank">2026 <em>Fortune</em> Best Workplaces in BioPharma™ List</a>. This is Dianthus’ inaugural appearance on the list, ranking among the top 30 small- and medium-sized biotechnology and pharmaceutical companies in the United States. The Company was recognized for fostering a high-trust and engaging workplace culture.</p> <p>“As Dianthus http://www.streetinsider.com/Globe+Newswire/Dianthus+Therapeutics+Recognized+Among+Fortune%E2%80%99s+2026+Best+Workplaces+In+BioPharma/27178001.html Tue, 13 Oct 2026 08:45:00 -0400 DNTH http://www.streetinsider.com/Press+Releases/Dianthus+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27136968.html <p>NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company&apos;s independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>The inducement grants consist of non-qualified stock options to purchase an aggregate of 106,000 shares of the Company&apos;s http://www.streetinsider.com/Press+Releases/Dianthus+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27136968.html Thu, 01 Oct 2026 17:00:00 -0400 DNTH http://www.streetinsider.com/Globe+Newswire/Dianthus+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27136968.html <p>NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company&apos;s independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>The inducement grants consist of non-qualified stock options to purchase an aggregate of 106,000 shares of the Company&apos;s http://www.streetinsider.com/Globe+Newswire/Dianthus+Therapeutics+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27136968.html Thu, 01 Oct 2026 17:00:00 -0400 DNTH http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Press+Releases/Dianthus+Therapeutics+Highlights+Claseprubart+Data+Presentations+Planned+for+2026+AANEM+Annual+Meeting/27117608.html <p>NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=AJnXmL1JnFM0yZ7UvJKSKEv1W2O5hhOWGXV949LXDhzqMrvitLaRw6OVQPDTO6gTNNoQQw6YE_wIuIM79nQSMZxZLJMSTRtKr3qmWwZ-oeeTSlU4RV7LyIR45zNdHheRcIRD48JnZJyBWWdYlePeCGA45USbv4kmqea7zhmBXiyL0tmYV28me4pZWb0CrM9VZX02NkHyxm3khMNqbfgRu4_eXON2hcGN6GK5DUIiFEA=" rel="nofollow" target="_blank">American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting</a>, taking place September 29 to October 2, 2026 in Orlando, Florida.</p> <p>“Despite important advances in the treatment of generalized myasthenia gravis, there remains a need for therapies that can provide consistent disease control while reducing the treatment http://www.streetinsider.com/Press+Releases/Dianthus+Therapeutics+Highlights+Claseprubart+Data+Presentations+Planned+for+2026+AANEM+Annual+Meeting/27117608.html Tue, 29 Sep 2026 08:00:00 -0400 DNTH http://www.streetinsider.com/Globe+Newswire/Dianthus+Therapeutics+Highlights+Claseprubart+Data+Presentations+Planned+for+2026+AANEM+Annual+Meeting/27117608.html <p>NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=AJnXmL1JnFM0yZ7UvJKSKEv1W2O5hhOWGXV949LXDhzqMrvitLaRw6OVQPDTO6gTNNoQQw6YE_wIuIM79nQSMZxZLJMSTRtKr3qmWwZ-oeeTSlU4RV7LyIR45zNdHheRcIRD48JnZJyBWWdYlePeCGA45USbv4kmqea7zhmBXiyL0tmYV28me4pZWb0CrM9VZX02NkHyxm3khMNqbfgRu4_eXON2hcGN6GK5DUIiFEA=" rel="nofollow" target="_blank">American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting</a>, taking place September 29 to October 2, 2026 in Orlando, Florida.</p> <p>“Despite important advances in the treatment of generalized myasthenia gravis, there remains a need for therapies that can provide consistent disease control while reducing the treatment http://www.streetinsider.com/Globe+Newswire/Dianthus+Therapeutics+Highlights+Claseprubart+Data+Presentations+Planned+for+2026+AANEM+Annual+Meeting/27117608.html Tue, 29 Sep 2026 08:00:00 -0400 DNTH http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Sep+17++Filed+by%3A+CARR+EDWARD/27080955.html si-local-file:///var/storage/secattach/20260918/27080955.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Sep+17++Filed+by%3A+CARR+EDWARD/27080955.html Fri, 18 Sep 2026 16:36:00 -0400 DNTH http://www.streetinsider.com/Equity+Offerings/Dianthus+Therapeutics+%28DNTH%29+files+mixed+shelf/27080600.html <p>Dianthus Therapeutics (NASDAQ: DNTH) filed mixed shelf of:</p><p>COMMON STOCK</p><p>PREFERRED STOCK</p><p>DEBT SECURITIES</p><p>WARRANTS</p><p>UNITS</p><p><br /> </p> http://www.streetinsider.com/Equity+Offerings/Dianthus+Therapeutics+%28DNTH%29+files+mixed+shelf/27080600.html Fri, 18 Sep 2026 16:08:13 -0400 DNTH http://www.streetinsider.com/Corporate+News/Dianthus+Therapeutics+%28DNTH%29+files+mixed+shelf/27080600.html <p>Dianthus Therapeutics (NASDAQ: DNTH) filed mixed shelf of:</p><p>COMMON STOCK</p><p>PREFERRED STOCK</p><p>DEBT SECURITIES</p><p>WARRANTS</p><p>UNITS</p><p><br /> </p> http://www.streetinsider.com/Corporate+News/Dianthus+Therapeutics+%28DNTH%29+files+mixed+shelf/27080600.html Fri, 18 Sep 2026 16:08:13 -0400 DNTH http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Dianthus+Therapeutics%2C+++++++++++++++/27080478.html si-local-file:///var/storage/secattach/20260918/27080478.html http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Dianthus+Therapeutics%2C+++++++++++++++/27080478.html Fri, 18 Sep 2026 16:02:00 -0400 DNTH http://www.streetinsider.com/SEC+Filings/Form++144++++++++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+CARR+EDWARD/27076215.html si-local-file:///var/storage/secattach/20260917/27076215.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+CARR+EDWARD/27076215.html Thu, 17 Sep 2026 16:28:00 -0400 DNTH http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+Dianthus+Therapeutics+%28DNTH%29+at+Overweight/27050076.html <p>JPMorgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ: DNTH) with a Overweight rating and a price target of $135.00.</p><p>The analyst comments: “DNTH is a clinical-stage biotech developing therapeutics for severe autoimmune diseases led by claseprubart, an active-C1s inhibitor, with an initial focus on complement-mediated neuromuscular disorders. While complement inhibition is an established tx in many neuromuscular disorders, current approved tx target the terminal pathway and are associated with infection-related safety concerns/boxed warning/REMS. DNTH is pursuing a differentiated strategy through active-C1s inhibition, which selectively blocks only the classical pathway. We believe this approach has the potential to deliver the http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+Dianthus+Therapeutics+%28DNTH%29+at+Overweight/27050076.html Fri, 11 Sep 2026 03:26:26 -0400 DNTH http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+Dianthus+Therapeutics+%28DNTH%29+at+Overweight/27050076.html <p>JPMorgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ: DNTH) with a Overweight rating and a price target of $135.00.</p><p>The analyst comments: “DNTH is a clinical-stage biotech developing therapeutics for severe autoimmune diseases led by claseprubart, an active-C1s inhibitor, with an initial focus on complement-mediated neuromuscular disorders. While complement inhibition is an established tx in many neuromuscular disorders, current approved tx target the terminal pathway and are associated with infection-related safety concerns/boxed warning/REMS. DNTH is pursuing a differentiated strategy through active-C1s inhibition, which selectively blocks only the classical pathway. We believe this approach has the potential to deliver the http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+Dianthus+Therapeutics+%28DNTH%29+at+Overweight/27050076.html Fri, 11 Sep 2026 03:26:26 -0400 DNTH http://www.streetinsider.com/New+Coverage/Citi+initiates+Dianthus+Therapeutics+coverage+with+Buy+rating/27026962.html <p>Citi analyst Samantha Semenkow initiated coverage of Dianthus Therapeutics (NASDAQ: DNTH) with a Buy rating and a price target of $156.00.</p><p>Semenkow noted that the company's lead drug, claseprubart, is a complement inhibitor targeting C1s with potential applications across multiple neuromuscular indications, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.</p><p>The analyst projects more than $5 billion in peak worldwide risk-adjusted revenue for claseprubart, citing proof-of-concept data that she said established a competitive efficacy profile and a dosing regimen of every two or four weeks.</p><p>Semenkow also noted two additional pipeline assets, DNTH212 and DNTH312, which the company is http://www.streetinsider.com/New+Coverage/Citi+initiates+Dianthus+Therapeutics+coverage+with+Buy+rating/27026962.html Fri, 04 Sep 2026 05:09:18 -0400 DNTH http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html <p>Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.</p><p>The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html Mon, 31 Aug 2026 08:00:00 -0400 BIIB DNTH VOR http://www.streetinsider.com/Hot+List+Pro/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html <p>Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.</p><p>The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG http://www.streetinsider.com/Hot+List+Pro/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html Mon, 31 Aug 2026 08:00:00 -0400 BIIB DNTH VOR http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html <p>Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.</p><p>The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html Mon, 31 Aug 2026 08:00:00 -0400 BIIB DNTH VOR